Major Shareholder Fairmount Funds Commits to AbbVie Acquisition of Apogee Therapeutics

summarizeSummary

Fairmount Funds, a major investor in Apogee Therapeutics, has formally agreed to vote its nearly 10% stake in favor of the company's acquisition by AbbVie for $135.11 per share, bolstering the deal's certainty.

check_boxKey Events · M&A and Partnerships · APGE

• Merger Agreement Confirmed

  Apogee Therapeutics will be acquired by AbbVie Inc. for $135.11 per share in cash, as previously announced on June 22, 2026.

• Major Shareholder Voting Agreement

  Fairmount Funds Management LLC, holding approximately 9.84% of Apogee's common stock, has entered into a voting agreement to support the merger. They committed to vote in favor of the deal and against any alternative transactions.

• Irrevocable Proxy Granted

  Fairmount Funds granted an irrevocable proxy to AbbVie to ensure their shares are voted for the merger, further solidifying the deal's path to completion.

• Director Resignation Noted

  Peter Harwin resigned from the Board of Directors on May 11, 2026, which the filing states was not due to any disagreement.

auto_awesomeAnalysis · APGE · Life Sciences

This Schedule 13D/A confirms the definitive agreement for AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash. Crucially, it discloses that Fairmount Funds Management LLC, a significant shareholder with approximately 9.84% ownership, has entered into a voting agreement to support the merger. This commitment from a major institutional investor significantly de-risks the merger's completion by ensuring a substantial block of votes in favor of the transaction, especially as the stock trades near its 52-week high, reflecting the acquisition premium.